Skip to main content

Table 1 Selection from entry cohort to samples of analysis

From: The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients

Sample Cohort 1996–97 Cohort 2003–04 Total
  N % N % N %
Entry cohort 389 100,0 488 100,0 877 100,0
./. loss-to-follow up 0 0,0 17 3,5 17 1,9
./. No stage information availablea 1 0,3 2 0,4 3 0,3
./. Stage 0b 22 5,7 33 6,8 55 6,3
./. Mx, M1c 20 5,1 26 5,3 46 5,2
./. Missings on marginal resectiond 1 0,3 12 2,5 13 1,5
Institutional-invasive sample 345 88,7 398 81,6 743 84,7
./. Non-residents 107 27,5 132 27,0 239 27,3
Regional-invasive sample 238 61,2 266 54,5 504 57,5
  1. Legend: arefers to non-assessable stage information, bexcludes non tissue invasive tumors (pTis), cexcluded all non-assessable metastasis status or distant metastasis, dpatients without any information are excluded